       Document 0495
 DOCN  M9640495
 TI    Erythropoietin.
 DT    9604
 AU    Fried W; Section of Hematology, Rush-Presbyterian-St. Luke's Medical;
       Center, Chicago, Illinois 60612, USA.
 SO    Annu Rev Nutr. 1995;15:353-77. Unique Identifier : AIDSLINE MED/96138948
 AB    Erythropoietin (Epo), the first growth factor to be discovered, is an
       endocrine hormone produced by specialized renal cells. The rate of Epo
       production is determined primarily by the oxygen demands of these renal
       cells relative to their oxygen supply. However, Epo production is
       modulated by various hormones, nutritional factors, cytokines, and the
       integrity of the erythron. Epo interacts with specific receptors found
       almost exclusively on erythroid progenitors. This interaction results in
       an expansion of the number of the erythroid progenitor and triggers late
       committed progenitors to undergo terminal maturation when provided with
       essential nutrients. Recombinant human Epo (rHuEpo) is commercially
       available for human use. It is safe, easily administered, and almost
       universally effective in treating the anemia of patients with renal
       failure. It has also been successful in treating the anemia of some
       patients with neoplasms, myelodysplastic syndromes, HIV infection,
       rheumatoid arthritis, and aplastic anemia. Much remains to be learned
       about the regulation of Epo production, the physiologic actions of Epo,
       and how best to use this growth factor in the treatment of anemia.
 DE    Anemia/DRUG THERAPY  Animal  Erythropoiesis/PHYSIOLOGY
       *Erythropoietin/GENETICS/PHYSIOLOGY/THERAPEUTIC USE  Human  JOURNAL
       ARTICLE  REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

